Regeneron Pharmaceuticals, Inc.【REGN】 業績・財務データ
市場
NASDAQ
| （単位：百万ドル） | 2010/12/31 | 2011/12/31 | 2012/12/31 | 2013/12/31 | 2014/12/31 | 2015/12/31 | 2016/12/31 | 2017/12/31 | 2018/12/31 | 2019/12/31 | 2020/12/31 | 2021/12/31 | 2022/12/31 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | 4,106 | 4,834 | 5,568 | 12,117 | 6,894 | |||||||||
| Sanofi collaboration revenue | ||||||||||||||
| Other collaboration revenue | ||||||||||||||
| Other revenue | ||||||||||||||
| Revenue from contract with customer | ||||||||||||||
| Research and development | ||||||||||||||
| Acquired in-process research and development | ||||||||||||||
| Selling, general, and administrative | ||||||||||||||
| Product | ||||||||||||||
| Cost of collaboration and contract manufacturing | ||||||||||||||
| Other operating (income) expense, net | ||||||||||||||
| Total expenses | ||||||||||||||
| Income from operations | ||||||||||||||
| Other income (expense), net | ||||||||||||||
| Interest expense | ||||||||||||||
| Total other income (expense) | ||||||||||||||
| Income before income taxes | ||||||||||||||
| Income tax expense | ||||||||||||||
| Net income | ||||||||||||||
| Earnings Per Share, Basic | ||||||||||||||
| Earnings Per Share, Diluted | ||||||||||||||
| Net income | ||||||||||||||
| Unrealized (loss) gain on debt securities | ||||||||||||||
| Unrealized gain (loss) on cash flow hedges | ||||||||||||||
| Comprehensive income | ||||||||||||||
Powered by Ponder (兄弟サイト)
アプリでもっと便利に
© 2016-2023 Strainer